Abbott Launches Third COVID-19 Test, A Laboratory-Based Antibody Blood Test

Via Abbott

Abbott (NYSE: ABT) announced today the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus (COVID-19). Antibody testing is an important next step to tell if someone has been previously infected. It will provide more understanding of the virus, including how long antibodies stay in the body and if they provide immunity. This type of knowledge could help support the development of treatments and vaccines.

This antibody test adds to Abbott’s existing COVID-19 tests that are already being used, including its m2000 molecular laboratory system and its ID NOW molecular point-of-care device.

“We continue to contribute in a significant and meaningful way by providing new solutions across our diagnostics testing platforms,” said Robert B. Ford, president and chief executive officer, Abbott. “I’m extremely proud of the many Abbott people who are working around the clock to get as many tests as we can to healthcare workers and patients.”

Antibody tests to expand testing and help healthcare workers
While molecular testing detects whether someone has the virus, antibody tests determine if someone was previously infected.

Abbott’s SARS-CoV-2 IgG test identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. Abbott’s IgG antibody test will initially be available on its ARCHITECT® i1000SR and i2000SR laboratory instruments*. More than 2,000 of these instruments are in use in U.S. laboratories. These instruments can run up to 100-200 tests per hour.

Abbott is making the test available as part of the U.S. Food and Drug Administration (FDA) notification without an Emergency Use Authorization (EUA) pathway outlined in Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. Additionally, Abbott plans to file an EUA submission with the FDA and plans to CE Mark to the IVD Directive (98/79/EC) in the European Union.

Abbott is significantly scaling up its manufacturing for antibody testing and is expecting to immediately ship close to 1 million tests this week to U.S. customers, and will ship a total of 4 million tests in total for April. The company is ramping up to 20 million tests in the U.S. in June and beyond as it expands the tests to run on its new Alinity i system. Abbott also will be expanding its laboratory antibody testing to the detection of the antibody, IgM, in the near future.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

*All ARCHITECT analyzers are Class 1 laser products.

SOURCE Abbott

For further information: Abbott Media: Kim Modory, 224-668-4696 or Darcy Ross, 224-667-3655; Abbott Investor Relations: Laura Dauer, 224-667-2299

MAA COVID-19 INFORMATION DISCLAIMER:

The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service.   The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.  

The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via email or other communications.

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER